Bradley S Snyder

Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.

Jeffrey D Bradley, Fenghai Duan, Abass Alavi, 2015, Journal of the National Cancer Institute.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

A Gregory Sorensen, Rajan Jain, Daniel P Barboriak, 2013, Neuro-oncology.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

A Gregory Sorensen, Kathleen M Schmainda, Daniel P Barboriak, 2015, Neuro-oncology.

Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non–Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235

Jeffrey D Bradley, Issam El Naqa, Fenghai Duan, 2016, The Journal of Nuclear Medicine.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Jeffrey D Bradley, Fenghai Duan, Janet S. Reddin, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.